Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

1. Histopathologically confirmed diagnosis of Langerhans cell histiocytosis according to the criteria defined by the Histiocyte Society * Demonstration of CD1a antigenic determinants on the surface of lesional cells (by immunocytology or immunohistology) or Birbeck granules in lesional cells by electron microscopy 2. Considered at risk or low risk according to the following criteria: 1. Multi-system at risk disease, defined as involvement of one or more risk organs (i.e., hematopoietic system, liver, spleen, or lungs) * No single-system lung involvement 2. Multi-system low-risk disease * Multiple organs involved but without involvement of risk organs 3. Single-system disease * Multifocal bone disease (i.e., lesions in 2 or more different bones) * Localized special site involvement, such as CNS-risk lesions with intracranial soft tissue extension or vertebral lesions with intraspinal soft tissue extension * Vault lesions are not regarded as CNS-risk lesions PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically documented solid tumor potentially expressing mutant ras Stage II/III adenocarcinoma of the lung following surgery or radiotherapy Limited or extensive small cell lung cancer in complete remission Dukes' C colorectal cancer following appropriate adjuvant chemotherapy Fully resected recurrent colorectal carcinoma Fully resected pancreatic carcinoma Tumor tissue available for determination of ras mutation Pa…